NYSE: PBHPrestige Consumer Healthcare Inc Stock
$70.14+0.01 (+0.01%)
Updated Apr 25, 2024
PBH Price
$70.14
Fair Value Price
N/A
Market Cap
$3.48B
52 Week Low
$52.90
52 Week High
$75.31
P/E
-43.84x
P/B
2.18x
P/S
2.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.13B
Earnings
-$80.67M
Gross Margin
55.2%
Operating Margin
-1.76%
Profit Margin
-7.1%
Debt to Equity
1.09
Operating Cash Flow
$241M
Beta
0.63
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PBH Overview
Prestige Consumer Healthcare Inc. manufactures over-the-counter health and personal care products in the U.S. and internationally. Offerings include BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. It sells its products through mass merchandisers, and drug, food, dollar, convenience, and club stores, as well as online. Prestige Consumer Healthcare was founded in 1996 and is headquartered in Tarrytown, NY.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PBH scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PBH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PBH is poor value based on its book value relative to its share price (2.18x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.07x)
P/B vs Industry Valuation
PBH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more PBH due diligence checks available for Premium users.
Be the first to know about important PBH news, forecast changes, insider trades & much more!
PBH News
Valuation
PBH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-43.84x
Industry
33.56x
Market
40.97x
PBH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.18x
Industry
2.07x
PBH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PBH's financial health
Profit margin
Revenue
$282.7M
Net Income
$53.0M
Profit Margin
18.8%
PBH's Earnings (EBIT) of -$19.94M... subscribe to Premium to read more.
Interest Coverage Financials
PBH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.3B
Liabilities
$1.7B
Debt to equity
1.09
PBH's short-term assets ($393.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PBH's long-term liabilities ($1.61B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PBH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PBH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$71.5M
Investing
-$4.5M
Financing
-$64.8M
PBH's operating cash flow ($241.01M)... subscribe to Premium to read more.
Debt Coverage Financials
PBH vs Pharmaceutical Stocks
Prestige Consumer Healthcare Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.